PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Formulation A (PF-07081532 20 mg plus 60 mg)
Drug: Formulation B (PF-07081532 80 mg)

First Posted Date: 2023-01-10

Last Posted Date: 2024-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT05677867

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Carfilzomib
Drug: Maplirpacept

First Posted Date: 2023-01-09

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT05675449

Locations: 🇺🇸
Clinical Research Advisors (Encino Satellite Location), Encino, California, United States
🇺🇸
Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California, United States
🇺🇸
Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles, California, United States

and more 28 locations

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ARV-471
Drug: Dabigatran etexilate

First Posted Date: 2023-01-06

Last Posted Date: 2024-08-16

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT05673889

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Phase 1

Terminated

Conditions: Obesity

Interventions: Drug: Semaglutide
Drug: PF-07081532

First Posted Date: 2023-01-05

Last Posted Date: 2025-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT05671653

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study to Learn About Recifercept in Patients With Achondroplasia

Completed

Conditions: Achondroplasia

Interventions: Other: Recifercept

First Posted Date: 2022-12-21

Last Posted Date: 2023-07-27

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT05659719

Locations: 🇺🇸
Pfizer, New York, New York, United States

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07328948
Drug: Placebo

First Posted Date: 2022-12-16

Last Posted Date: 2024-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT05654181

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Phase 3

Active, not recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: ARV-471
Drug: Fulvestrant

First Posted Date: 2022-12-16

Last Posted Date: 2025-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 624

Registration Number: NCT05654623

Locations: 🇺🇸
Morton Plant Hospital - BayCare Health System, Clearwater, Florida, United States
🇺🇸
3T Radiology LLC, Coconut Creek, Florida, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States

and more 395 locations

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Oral [14C]PF-07081532
Drug: Oral PF-07081532 and IV [14C]PF-07081532

First Posted Date: 2022-12-15

Last Posted Date: 2023-03-24

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT05652647

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ARV-471
Drug: Rosuvastatin

First Posted Date: 2022-12-15

Last Posted Date: 2024-07-26

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05652660

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

Phase 1

Completed

Conditions: Alopecia Areata

Interventions: Drug: Ritlecitinib 20 mg

First Posted Date: 2022-12-14

Last Posted Date: 2024-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT05650333

Locations: 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸
Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy